UNSPSC 51411714: Pimefylline nicotinate

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C15H18N6O2.C6H5NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y694512DA, chemically known as nicotinic acid, compd. with 7-(2-((3-pyridylmethyl)amino)ethyl)theophylline (1:1), but more generally known as pimefylline nicotinate, which bears US NIH Compound Identifier 197889.

European Medicines Agency schedules pimefylline nicotinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09837MIG. Most nations, for tariff purposes, schedule pimefylline nicotinate under HS 29395900. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CCNCC3CCCNC3.C1CC(CNC1)C(=O)O.

UNSPSC 51411714 Pimefylline nicotinate is a Commodity code for a specific pharmaceutical active pharmaceutical ingredient that state and local governments procure primarily as part of Advanced Life Support (ALS) medication supplies and broader generic pharmaceutical purchasing programs. State and local jurisdictions acquire this substance through direct medication procurement contracts for emergency medical services, pharmacy benefit programs, and multi-state cooperative purchasing arrangements. The issuing bodies include city purchasing departments (fire rescue services), state health and human services agencies, and multi-state cooperative purchasing alliances. Scope of work centers on pharmaceutical supply contracts that require vendors to meet strict regulatory compliance, including FDA certification, current Good Manufacturing Practices (cGMP) compliance, Drug Supply Chain Security Act (DSCSA) adherence, OSHA Safety Data Sheet standards, and accessibility documentation requirements such as WCAG 2.2 Level AA and Section 508 conformance. Contracts typically mandate firm fixed pricing inclusive of freight and taxes, expiration-date guarantees of nine months minimum from delivery, warranty of 365-day defect-free performance, and replacement obligations for expired stock.

Geographic activity spans Florida, Texas, and Minnesota through recent solicitations. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with a response date of April 8, 2026, and an estimated contract value of $40,000, designated as a Small Local Business Enterprise sheltered market with a 5 percent bid discount for SLBE participation not to exceed $10,000. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring distribution through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) and a two-year contract term with pricing weighted at 75 percent of evaluation criteria and a mandatory 3 percent administrative fee on all purchases.